## Taku Nakashima

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2411498/publications.pdf

Version: 2024-02-01

60 papers 1,018 citations

<sup>394421</sup> 19 h-index 29 g-index

60 all docs 60 docs citations

60 times ranked

1803 citing authors

#	Article	IF	CITATIONS
1	Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis. Disease Markers, 2016, 2016, 1-8.	1.3	91
2	Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. Respiratory Investigation, 2019, 57, 451-459.	1.8	76
3	Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor- $\hat{l}^2$ -Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts. PLoS ONE, 2016, 11, e0148969.	2.5	57
4	FIZZ2/RELM- $\hat{I}^2$ Induction and Role in Pulmonary Fibrosis. Journal of Immunology, 2011, 187, 450-461.	0.8	56
5	Bone Marrow CD11c+ Cell–Derived Amphiregulin Promotes Pulmonary Fibrosis. Journal of Immunology, 2016, 197, 303-312.	0.8	45
6	Suppressor of cytokine signaling 1 inhibits pulmonary inflammation and fibrosis. Journal of Allergy and Clinical Immunology, 2008, 121, 1269-1276.	2.9	43
7	Essential role of stem cell factor–câ€Kit signalling pathway in bleomycinâ€induced pulmonary fibrosis. Journal of Pathology, 2013, 230, 205-214.	4.5	34
8	Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. Lung Cancer, 2018, 119, 21-24.	2.0	34
9	Overproduction of collagen and diminished SOCS1 expression are causally linked in fibroblasts from idiopathic pulmonary fibrosis. Biochemical and Biophysical Research Communications, 2007, 353, 1004-1010.	2.1	30
10	Mesenchymal-Specific Deletion of C/EBP $\hat{l}^2$ Suppresses Pulmonary Fibrosis. American Journal of Pathology, 2012, 180, 2257-2267.	3.8	30
11	Serum highâ€mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis. Respirology, 2020, 25, 275-280.	2.3	30
12	Lung Bone Marrow–derived Hematopoietic Progenitor Cells Enhance Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 976-984.	5.6	25
13	Albumin–globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. International Journal of Clinical Oncology, 2020, 25, 74-81.	2.2	25
14	A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline. BMJ Open, 2014, 4, e005090-e005090.	1.9	23
15	Inhibition of PAIâ€1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancerâ€associated fibroblasts. Journal of Cellular and Molecular Medicine, 2019, 23, 2984-2994.	3.6	23
16	Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome. Journal of Internal Medicine, 2008, 263, 432-439.	6.0	22
17	Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice. Molecular Therapy - Nucleic Acids, 2018, 12, 698-706.	5.1	22
18	High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery. Medicine (United States), 2019, 98, e14296.	1.0	21

#	Article	IF	CITATIONS
19	Suplatast tosilate protects the lung against hyperoxic lung injury by scavenging hydroxyl radicals. Free Radical Biology and Medicine, 2017, 106, 1-9.	2.9	19
20	ILâ€12p40 is essential for the downâ€regulation of airway hyperresponsiveness in a mouse model of bronchial asthma with prolonged antigen exposure. Clinical and Experimental Allergy, 2009, 39, 290-298.	2.9	18
21	Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma. European Respiratory Journal, 2018, 51, 1701610.	6.7	16
22	Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1. Cancer Letters, 2019, 442, 31-39.	7.2	15
23	Nicergoline Improves Dysphagia by Upregulating Substance P in the Elderly. Medicine (United States), 2011, 90, 279-283.	1.0	14
24	Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine Lung. Pharmaceutical Research, 2015, 32, 3877-3885.	3.5	14
25	Clinically remitted childhood asthma is associated with airflow obstruction in middleâ€aged adults. Respirology, 2017, 22, 86-92.	2.3	14
26	Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress. Free Radical Biology and Medicine, 2019, 136, 52-59.	2.9	14
27	The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 131-139.	2.3	14
28	Mucins Carrying Selectin Ligands as Predictive Biomarkers of Disseminated Intravascular Coagulation Complication in ARDS. Chest, 2011, 139, 296-304.	0.8	13
29	C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis. Respiration, 2019, 98, 212-220.	2.6	13
30	Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer. Anticancer Research, 2019, 39, 5725-5731.	1.1	13
31	Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 145.	3.6	13
32	Photochemical generation of the 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) radical from caged nitroxides by near-infrared two-photon irradiation and its cytocidal effect on lung cancer cells. Beilstein Journal of Organic Chemistry, 2019, 15, 863-873.	2.2	12
33	Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis. Respiratory Investigation, 2020, 58, 465-472.	1.8	11
34	Plasminogen activator inhibitor‑1 serves an important role in radiation‑induced pulmonary fibrosis. Experimental and Therapeutic Medicine, 2018, 16, 3070-3076.	1.8	9
35	Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma. Medicine (United States), 2019, 98, e14821.	1.0	9
36	Chronic Intestinal Pseudo-obstruction and Orthostatic Hypotension Associated with Small Cell Lung Cancer that Improved with Tumor Reduction after Chemoradiotherapy. Internal Medicine, 2017, 56, 2627-2631.	0.7	8

#	Article	IF	CITATIONS
37	<i>AGER</i> rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma. Oncotarget, 2017, 8, 94382-94392.	1.8	8
38	Metastatic Breast Cancer Presenting as Air-space Consolidation on Chest Computed Tomography. Internal Medicine, 2009, 48, 727-731.	0.7	7
39	Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients. Internal Medicine, 2019, 58, 915-920.	0.7	7
40	Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis. Stem Cell Research and Therapy, 2021, 12, 506.	5 <b>.</b> 5	7
41	Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody. Medicine (United States), 2018, 97, e13542.	1.0	6
42	Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis. Internal Medicine, 2019, 58, 3129-3132.	0.7	6
43	Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease. Respiratory Medicine, 2020, 172, 106131.	2.9	6
44	Chronic Hepatitis C Virus Infection is Associated with More Severe Asthma. Allergology International, 2011, 60, 299-304.	<b>3.</b> 3	5
45	MT 95â€4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model. Cancer Science, 2015, 106, 921-928.	3.9	5
46	Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study. In Vivo, 2018, 32, 1155-1160.	1.3	5
47	Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 1079-1084.	1.4	5
48	Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma. Clinical Respiratory Journal, 2021, 15, 48-55.	1.6	5
49	Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity. Stem Cell Research and Therapy, 2021, 12, 471.	5.5	4
50	Alternateâ€'day administration of Sâ€'1 for elderly patients with advanced nonâ€'smallâ€'cell lung carcinoma: A prospective feasibility study. Molecular and Clinical Oncology, 2018, 9, 539-544.	1.0	3
51	Coexisting TIF1 $\hat{I}^3$ -positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1 $\hat{I}^3$ Antibody-positive Dermatomyositis. Internal Medicine, 2020, 59, 2553-2558.	0.7	3
52	Pulmonary arteriovenous malformation exhibiting recanalization > 10 years after coil embolization. Medicine (United States), 2020, 99, e18694.	1.0	3
53	Risk factors associated with increased discontinuation rate of trimethoprim–sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study. Pulmonary Pharmacology and Therapeutics, 2021, 67, 101999.	2.6	3
54	Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis. Internal Medicine, 2017, 56, 3327-3331.	0.7	2

#	Article	IF	CITATIONS
55	Clinical utility of CCL15 as a prognostic biomarker for hypersensitivity pneumonitis., 2019,,.		1
56	Serum high mobility group box $1$ is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis., $2019$ ,,.		1
57	CS15-5. Recruitment of bone marrow derived CD11c+ and c-Kit+ cells in pulmonary fibrosis. Cytokine, 2011, 56, 104.	3.2	O
58	Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 871-877.	2.9	0
59	Clinically remitted childhood asthma is a risk factor for airflow obstruction in middle-aged adults. , 2015, , .		0
60	Fine crackles quantitative value can help the diagnosis of interstitial lung diseases – Clinical utility of the innovative analyzing system of respiratory sounds. , 2019, , .		0